..
Eli suomeksi?Alkuperäinen kirjoittaja huolestunut:... kerrotaan mm. näin:
2.9 Business plan for the global pandemic influenza action plan
Solution 1. Promote seasonal vaccine programmes. This was fundamental to create
greater capacity. It is also cost-effective in reducing health-care spending and loss of
workdays. Concerns included the high cost of influenza vaccine, which may divert
funds from other public health priorities. Since capacity in 2010 is projected to be
substantially higher than forecast demand, another issue was the need for incentives
for industry to maintain such production levels. Finally, it was noted that even if each
country achieved the highest rate of seasonal influenza vaccination currently achieved
in the same economical status stratum (high, middle or low income), demand would
still not create the capacity needed to meet the GAP goal.
Solution 2. Maintain production capacity beyond seasonal need after 2010. The main
issue here is flexibility in maintaining capacity, e.g. rotating production lines and
ensuring that supplies, equipment and human resources are available and functional
at short notice. As noted in Solution 1, encouraging industry to maintain capacity and
regular batch testing would be needed to meet surge demand.
Solution 3. Convert IIV to LAIV capacity at the onset of a pandemic. Facility
conversion is a rapid technique that could bridge the supply-demand gap by 2012,
based on prudent estimates that a dose of trivalent IIV yields 15-30 courses of pandemic
LAIV. Considerations included the outstanding clinical and regulatory work to
broaden the indication for LAIV, the significant up-front preparation for conversion,
and IP hurdles. It was also suggested that establishing new plants in regions without
access to pandemic influenza vaccine would be as cost-effective as converting existing
capacity to LAIV production.
23
http://whqlibdoc.who.int/hq/2009/WHO_IVB_09.05_eng.pdf